Compare BUD & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUD | ABT |
|---|---|---|
| Founded | 1366 | 1888 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.0B | 173.2B |
| IPO Year | 2016 | 2007 |
| Metric | BUD | ABT |
|---|---|---|
| Price | $75.06 | $98.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 27 |
| Target Price | $95.62 | ★ $120.74 |
| AVG Volume (30 Days) | 2.1M | ★ 5.6M |
| Earning Date | 10-29-2026 | 10-21-2026 |
| Dividend Yield | 1.09% | ★ 2.57% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $44,328,000,000.00 |
| Revenue This Year | $9.09 | $13.25 |
| Revenue Next Year | $3.92 | $8.62 |
| P/E Ratio | ★ $23.27 | $160.85 |
| Revenue Growth | N/A | ★ 5.67 |
| 52 Week Low | $58.82 | $81.97 |
| 52 Week High | $86.60 | $135.13 |
| Indicator | BUD | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 38.24 |
| Support Level | $71.57 | $86.56 |
| Resistance Level | $81.15 | $104.19 |
| Average True Range (ATR) | 1.12 | 2.08 |
| MACD | -0.20 | -0.26 |
| Stochastic Oscillator | 34.89 | 28.13 |
Anheuser-Busch InBev is the largest brewer in the world and one of the top five consumer product companies by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 acquired SABMiller.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.